Market Performance And Growth PotentialAnalysts see more upside than downside for Medtronic over the next twelve months, driven by consistent revenue growth and potential contribution from new product launches.
Product Approvals And InnovationThe company has received FDA approval for the Affera PFA platform and CMS TPT payment approval for the Symplicity renal denervation system, with further FDA submission for Hugo planned.
Revenue And Earnings GrowthMedtronic increased its full-year revenue guidance, signaling confidence in its future performance.